Clinical Trial Update: Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating an injection of Brimonidine tartrate ophthalmic 0.025% in patients using Netarsudil 0.02%/Latanoprost 0.005% to treat glauco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• Brimonidine tartrate ophthalmic solution 0.025% (Brimonidine tartrate)
• Netarsudil 0.02% / Latanoprost 0.005% fixed-dose combination (Netarsudil/latanoprost fixed-dose combination)

Snippet

Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Conditions: Glaucoma | Phase 4 | Status: RECRUITING